Rakovina Therapeutics plans to amend terms of warrants, debentures, and common share purchase warrants

From GlobeNewswire: 2025-06-30 22:03:00

Rakovina Therapeutics Inc. (TSXV: RKV) plans to amend the terms of its outstanding warrants and convertible debentures, with changes including an extension of the maturity date and a reduction in conversion price. The amendments are subject to approval from the Exchange and holders of the securities. The Company also intends to amend the terms of its common share purchase warrants, aiming to reduce the exercise price and term. These changes are also contingent on Exchange approval. Rakovina Therapeutics focuses on developing cancer treatments using AI-powered technologies for targeting DNA damage response.



Read more at GlobeNewswire: Rakovina Therapeutics Announces Intention to Amend